Even though BRAF, KRAS and NRAS mutations, cancer progression and mortality were more prevalent in the vitamin C deficient group, the differences between groups did not reach statistical significance (12% in the adequate plasma vitamin C group vs. 31% in the low plasma vitamin C, p = 0.139) (Table 3). Here, KRAS is linked to cancer.